[12]Miklos Z. Molnar, Kamyar Kalantar-Zadeh, Evan H. Lott, Jun Ling Lu, et al.ACEI and ARB and Mortality in Chronic Kidney Disease.Journal of the American College of Cardiology,2014:650-658.
[14]Knoll GA，Hun RC，Schyal’A，et al.Renin- angiotensin system blockade and the risk of hyperkalemia in chronic hemodialysis patients[J].Am J Med,2002，112(2)：110-114.
[15]Jesse Theisen-Toupal.Hypokalemia and Hyperkalemia. Review Article Hospital Medicine Clinics,2015,4(1):34-50.
[17]Muschart X , Boulouffe C , Jamart J , et al. A determination of the current causes of hyperkalaemia and whether they have changed over the past 25 years[J]. acta clinica belgica, 2014, 69(4):280-284.
[21]JADOUL M, THUMMA J, FULLER D S, et al. Modifiable practices associated with sudden death among hemodialysis patients in the dialysis outcomes and practice patterns study[J]. Clin J Am Soc Nephrol,2012,7(5):765-774.
[22]PUN P H, LEHRICH R W, HONEYCUTT E F, et al. Modifiable risk factors associated with sudden cardiac arrest within hemodialysis clinics [J]. Kidney Int, 2011,79(2):218-227.
[23]MUNOZ R I, MONTENEGRO J, SALCEDO A, et al.Effect of acetate-free biofiltration with a potassium-profiled dialysate on the control of cardiac arrhythmias in patients at risk: a pilot study [J]. Hemodial Int,2008,12(1):108-113.
[26]NELMS M N, SUCHER K P, LACEY K, et al. Nutrition Therapy and Pathophysiology [M].2nd Edition Nelms: Cengage Learning, 2010.
[27]PANI A, FLORIS M, ROSNER MH, et al. Hyperkalemia in hemodialysis patients[J]. Semin Dial, 2014,27(6):571-576.
[28]Filiopoulos V, Koutis I, Trompouki S, et al. Lanthanum Carbonate Versus Sevelamer Hydrochloride: Improvement of Metabolic Acidosis and Hyperkalemia in Hemodialysis Patients[J]. Therapeutic Apheresis & Dialysis,2011,15(1):20-27.
[30]CHAABAN A, ABOUCHACRA S, GEBRAN N, et al. Potassium binders in hemodialysis patients: a friend or foe? [J].Ren Fail,2013,35(2):185-188.
[31]Rosano GMC, Spoletini I, Agewall S.Pharmacology of new treatments for hyperkalaemia: patiromer and sodium zirconium cyclosilicate[J].Eur Heart J Suppl,2019,21(Suppl A):A28-A33.
[32]Palmer BF.Potassium Binders for Hyperkalemia in Chronic Kidney Disease-Diet, Renin-Angiotensin-Aldosterone System Inhibitor Therapy, and Hemodialysis[J].Mayo Clin Proc,2020,95(2):339-354.
[33]Sterns RH, Rojas M, Bernstein P, et al. Ion-exchange resins for the treatment of hyperkalemia: are they safe and effective?[J]. J Am Soc Nephrol,2010,21(5):733-735.
[34]Li T，Vijayan A. Insulin for the treatment of hyperkalemia： a double-edged sword?[J]. Clin Kidney J,2014,7(3):239-241.
[35]Bushinsky DA，Williams GH，Pitt B, et al. Patiromer induces rapid and sustained potassium lowering in patients with chronic kidney disease and hyperkalemia[J]. Kidney Int,2015,88(6):1427-1433.
[36]Stavros F，Yang A，Leon A, et al. Characterization of structure and function of ZS-9，a K+ selective ion trap[J]. PLoS One,2014,9(12):e114686.
[37]Kosiborod M，Rasmussen HS，Lavin P，et al. Effect of sodium zirconium cyclosilicate on potassium lowering for 28 days among outpatients with hyperkalemia：the HARMONIZE randomized clinical trial[J]. JAMA，2014，312（21）：2223- 2233.
